Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Loss per share

Loss per share

12 Months Ended

Mar. 31, 2024

Note 6 — Loss per share


	As of March 31,
	2024			2023			2022
Loss for the year attributable to Virax		(6,733,537	)		(5,457,494	)		(1,708,827	)
Basic and diluted loss per share attributable to Virax – ordinary shares		(3.36	)		(5.13	)		(1.79	)

Basic loss per share is calculated by dividing the loss for the year by the weighted average number of ordinary shares in issue during the financial year. This calculation takes into effect the Share Consolidation as discussed in Note 18.

Diluted loss per share

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue during the year to assume conversion of all dilutive potential ordinary shares. The Company had no dilutive shares for the years ended March 31, 2024, 2023 and 2022. This calculation takes into effect the Share Consolidation as discussed in Note 18. The Company's basic and dilutive loss per share as of March 31, 2024, 2023, and 2022 are as follows:


	As of March 31,
	2024		2023		2022
Weighted average number of ordinary shares used in basic and diluted loss per share (Ordinary shares)		2,006,414		1,062,984		956,326
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted loss per share(1)		2,006,414		1,062,984		956,326

(1)

For the years ended March 31, 2024, 2023 and 2022, potential ordinary shares are anti-dilutive, as their inclusion in the diluted loss per share calculation would reduce the loss per share, and hence have been excluded.